1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Liraglutide |
| brand | String | Victoza (T2DM), Saxenda (obesity) |
| structure | File | |
| classes | List of String, delimiter: , | [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · [[Cardiovascular risk reduction]] agent |
| mechanism | String | Once-daily agonist of the [[GLP-1 receptor]]. |
| uses | String | [[Type 2 diabetes mellitus]] (incl. pediatric ≥10 y) · [[Obesity]] (incl. pediatric ≥12 y) · [[Cardiovascular risk reduction]] in T2DM |
| starting_dose | String | Victoza: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000181-QINU`"' · Saxenda: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000182-QINU`"' |
| preparations | String | Pre-filled multi-dose pen (3 mL): Victoza 6 mg/mL (0.6 / 1.2 / 1.8 mg per day);'"`UNIQ--ref-00000183-QINU`"' Saxenda 6 mg/mL (0.6 / 1.2 / 1.8 / 2.4 / 3.0 mg per day)'"`UNIQ--ref-00000184-QINU`"' |
| fda_max | String | 1.8 mg/day SC (Victoza, T2DM)'"`UNIQ--ref-00000185-QINU`"' · 3.0 mg/day SC (Saxenda, obesity)'"`UNIQ--ref-00000186-QINU`"' |
| pill_id | Text | |
| routes | List of String, delimiter: , | Subcutaneous (abdomen • thigh • upper arm); same time each day • with or without food'"`UNIQ--ref-00000187-QINU`"' |
| onset | String | Glycemic effect within days; weight effect over weeks to months'"`UNIQ--ref-00000188-QINU`"' |
| duration | String | ~24 h (daily dosing)'"`UNIQ--ref-00000189-QINU`"' |
| halflife | String | ~13 hours'"`UNIQ--ref-0000018A-QINU`"' |
| bioavailability | String | SC ~55%'"`UNIQ--ref-0000018B-QINU`"' |
| pregnancy | String | Avoid. Discontinue before planned pregnancy.'"`UNIQ--ref-0000018C-QINU`"' |
| legal | String | Rx-only;'"`UNIQ--ref-0000018D-QINU`"' not a controlled substance |
